Cilostazol

Research use only, not for human use.

Cilostazol (OPC 13013, OPC 21) is a potent inhibitor of PDE3A with IC50 of 0.2 uM; inhibits platelet aggregation and has considerable antithrombotic effects in vivo.

Cilostazol (OPC 13013, OPC 21) is a potent inhibitor of PDE3A with IC50 of 0.2 uM; inhibits platelet aggregation and has considerable antithrombotic effects in vivo. The compound relaxes vascular smooth muscle and inhibits mitogenesis and migration of vascular smooth muscle cells; also upregulates autophagy via SIRT1 activation, has preventive effects on various central nervous system (CNS) diseases.Stroke Approved

OPC 13013;OPC 21

Angiogenesis

PDE

PDE3

Neurological Disease

Stroke

73963-72-1

369.46

C20H27N5O2

>98% (HPLC)

10 mM in DMSO

C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4

2(1H)-Quinolinone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-

(-20℃)

With Ice Pack

≥ 2 years